Asher Bio Launches with $55 Million Series A Financing Led by …

Mar 23, 2021  · South San Francisco, Calif., March 23, 2021 – Asher Biotherapeutics, a biotechnology company developing precisely targeted immunotherapies for cancer and other …


Install CouponFollow Chrome Extension   CouponFollow Extension

$55
OFF

Asher Bio Launches With $55 Million Series A Financing Led By …

3 weeks from now

Mar 23, 2021  · South San Francisco, Calif., March 23, 2021 – Asher Biotherapeutics, a biotechnology company developing precisely targeted immunotherapies for cancer and other …

asherbio.com

$55
OFF

Asher Bio Bursts On The Scene With $55M Series A

3 weeks from now

Mar 23, 2021  · SOUTH SAN FRANCISCO, Calif.—Asher Biotherapeutics announced its launch today, following a $55 million Series A financing led by Third Rock Ventures with participation …

drugdiscoverynews.com

$55
OFF

Press Releases - Asher Bio

3 weeks from now

Jan 8, 2025  · Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials. April 3, 2024 ... Asher Bio Closes $108 Million Series B Financing. …

asherbio.com

$55
OFF

Asher Bio Sets Out With $55M To Deliver The Pros Of Cytokines, …

3 weeks from now

Mar 23, 2021  · Asher Bio launches with $55 million to advance a suite of immunotherapies, including cytokine treatments, that only activate a targeted cell type. The series A round, …

fiercebiotech.com

$55
OFF

HEALTH CARE New Twist On Old Cancer Target Brings $55M To …

3 weeks from now

Asher Bio Inc. collected a $55 million Series A round led by Third Rock Ventures, it said today. Other back - ers include Tavistock Group’s Boxer Capital, Invus, Y Combinator, where the …

asherbio.com

$55
OFF

Asher Raises $55 Million Series A For Targeted Cancer ... - BioSpace

3 weeks from now

Mar 23, 2021  · Targeted immunotherapy company Asher Bio launched today with a $55 million Series A round led by Third Rock Ventures, aiming to move its lead engineered interleukin-2 …

biospace.com

$55
OFF

Asher Bio Adds $55M And Takes A Page From Nature For Cancer ...

3 weeks from now

Mar 23, 2021  · It is coming out of stealth with $55 million and a plan to bring its lead program into human testing next year. Third Rock Ventures led Asher’s Series A round of financing.

medcitynews.com

$55
OFF

Series A - Asher Bio - 2021-03-23 - Crunchbase Funding Round …

3 weeks from now

Mar 23, 2021  · Asher Bio — Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel …

crunchbase.com

$55
OFF

Asher Bio Raises $55M In Series A Financing - FinSMEs

3 weeks from now

Mar 23, 2021  · Asher Biotherapeutics, a South San Francisco, Calif.-based biotechnology company developing precisely targeted immunotherapies for cancer and other diseases, …

finsmes.com

$55
OFF

Asher Bio Closes $55M Series A Round For Targeted IL-2 Drugs

3 weeks from now

Mar 23, 2021  · Asher Biotherapeutics Inc. raised $55 million in a series A financing round to take forward a series of engineered cytokines designed to selectively activate T cells or other …

bioworld.com

$55
OFF

Asher Bio Launches With $55 Million In Funding

3 weeks from now

Mar 26, 2021  · Asher Bio has launched with $55 million in series A funding led by Third Rock Ventures. The company’s cis-targeting technology aims to overcome common problems in …

acs.org

$55
OFF

Biotech Asher Secures $55 Million Funding: Phase 1B Trials On The …

3 weeks from now

Apr 17, 2024  · Asher Biotherapeutics, a leader in developing targeted immunotherapies, has secured $55 million in Series C funding led by RA Capital Management. This investment will …

clinicaltrialvanguard.com

$55
OFF

Asher Biotherapeutics: $55 Million Raised To Develop Precisely …

3 weeks from now

Apr 17, 2024  · Asher Biotherapeutics, a biotechnology company that is developing precisely targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the …

pulse2.com

$55
OFF

Asher Bio Launches With $55 Million Series A Financing Led By …

3 weeks from now

Mar 23, 2021  · Asher Bio Launches with $55 Million Series A Led by Third Rock to Discover & Develop Highly Specific Immunotherapies Using a Novel Technology Platform Social Media …

businesswire.com

$55000000
OFF

Founder Lodge | Asher Biotherapeutics Raises $55,000,000 At Series …

3 weeks from now

Apr 17, 2024  · Series C; $55,000,000 ; Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform …

founderlodge.com

$55
OFF

Asher Bio Launches With $55 Million Series A Financing Led By …

3 weeks from now

On March 23, 2021 Asher Biotherapeutics, a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases, reported its launch following a $55 …

1stoncology.com

$55
OFF

Asher Bio Closes $55 Million Series C Financing To Advance Lead …

3 weeks from now

Apr 16, 2024  · South San Francisco, Calif., April 16, 2024 – Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, …

asherbio.com

$55
OFF

Asher Bio Closes $55M Series C Financing - FinSMEs

3 weeks from now

Apr 17, 2024  · Asher Bio, a San Francisco, CA-based biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, raised …

finsmes.com

$55
OFF

Asher Bio Closes $55 Million Series C Financing To Advance

3 weeks from now

Asher Bio plans to use the proceeds from this financing to advance the clinical development of its lead program, AB248, a novel CD8+ T cell selective IL-2, generated by fusing a reduced …

nasdaq.com

$55
OFF

Asher Bio Secures $55M In Series C Funding For Cancer Therapy

3 weeks from now

Apr 18, 2024  · Asher Biotherapeutics raises $55 million in Series C funding led by RA Capital, with AstraZeneca and Bristol Myers Squibb among new investors. ... $55 million raised in …

sliceofhealthcare.com

FAQs about Asher Bio Launches with $55 Million Series A Financing Led by … Coupon?

What happened to Asher Biotherapeutics?

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of a Series C financing, raising $55 million. South San Francisco, Calif., April 16, 2024 ...

What is Asher Bio?

Asher Bio is a biotech company founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and located in South San Francisco. For more information, please visit www.asherbio.com and follow us on X (formerly Twitter) @AsherBio and on LinkedIn. ...

Where is Asher bio located?

Asher Bio is backed by Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn. ...

Is Asher bio a breakthrough cytokine immunotherapy solution?

Jeffrey Tong, PhD, Partner at Third Rock Ventures said, “Following an exhaustive assessment of the cytokine immunotherapy landscape, Third Rock is excited to partner with Asher Bio and their unique approach, which we believe has breakthrough potential to generate multiple differentiated product candidates.” ...

What is Asher Bio's AB248?

Asher Bio's lead program, AB248, is a novel CD8+ T cell selective IL-2. It was generated by fusing a reduced potency IL-2 mutein to an anti-CD8β antibody. Asher Bio plans to use the proceeds from this financing to advance the clinical development of AB248. ...

What makes Asher bio unique?

Craig Gibbs, PhD, Chief Executive Officer of Asher Bio, said, “Our founders had the insight to focus on designing immunotherapies that would only have their effect on defined immune cell subtypes rather than trying to localize the effect of inherently non-specific molecules. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension